Looking ahead, the market is projected to reach approximately USD 268.37 billion by 2034, growing steadily at a strong CAGR of 17.5% from 2025 to 2034
By Eleanor Malone The worlds biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market
Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304
Microparticles can be formulated into diverse dosage forms such as dry powders, injectable suspensions (e.g., microspheres and liposomes), and are suitable for multiple routes of administration, including oral, pulmonary, and parenteral delivery, as summarized in Table 1B
Practitioner-grade supplements are available through HormoneSynergy Longevity Medicine in Portland and Lake Oswego, Oregon
So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss